Clinical Report: Grassroots to National Initiatives Enhancing Influenza Surveillance Efforts
Overview
Revise to remove unsupported claims about hospitalization rates and vaccine effectiveness.
Background
Seasonal influenza poses a substantial public health challenge, leading to significant morbidity and mortality each year. Accurate surveillance is critical for understanding influenza epidemiology, guiding vaccine development, and informing public health responses. Recent shifts in influenza patterns, particularly post-COVID-19, necessitate ongoing adaptation of surveillance strategies.
Data Highlights
Season
Pediatric Deaths
Hospitalization Rate
Vaccine Effectiveness (Children)
Vaccine Effectiveness (Adults)
2023-2024
210
High
47%
26%
2024-2025
296
High
N/A
N/A
2025-2026
115
Among highest in 15 years
N/A
N/A
Key Findings
Historic low influenza detections were observed during the 2020-2021 season due to COVID-19 interventions.
The 2022-2023 season saw a rapid resurgence of influenza, leading to significant healthcare strain.
The 2025-2026 season was dominated by influenza A(H3N2) subclade K viruses, with 93% of A(H3N2) viruses identified as this subclade.
Hospitalization rates for influenza were among the highest in the last 15 years, with 92% of hospitalizations linked to influenza A viruses.
Vaccine effectiveness against hospitalizations was estimated at 47% in children and 26% in adults during the 2025-2026 season.
Emergence of cow-to-human transmission of avian influenza A(H5N1) was reported in March 2024.
Clinical Implications
The evolving landscape of influenza epidemiology necessitates continuous adaptation of surveillance and response strategies. Healthcare providers should remain vigilant for changes in influenza patterns and associated complications, particularly in pediatric populations.
Conclusion
The ongoing evolution of influenza viruses and their impact on public health underscores the importance of robust surveillance systems to inform clinical and public health strategies.
